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Each year the American Society for Blood and Marrow Transplantation presents Best Abstract Awards to recognize
outstanding research in the basic sciences that contribute to the advancement of the field of blood and marrow trans-
plantation. The abstracts receiving the award are those that were scored highest by the Abstract Review Committees.
Each award is accompanied by a prize of $1,000.1
ENGINEERING CD19-REDIRECTED T LYMPHOCYTES TO ENHANCE THEIR
SAFETY AND EFFICACY
Hoyos, V., Savoldo, B., Vera, J.F., Quintarelli, C., Heslop, H.,
Rooney, C.M., Brenner, M.K., Dotti, G. Baylor College of Medicine,
Houston, TX
Recurrence of disease remains the largest cause of mortality for
high-risk leukemia and lymphoma patients receiving stem cell trans-
plant. Generation of T lymphocytes expressing a chimeric antigen
receptor (CAR) targeting CD19 represents an attractive strategy to
maintain remission after conventional treatment. However, the clin-
ical benefit of this strategy is limited by poor expansion of T cells
within the tumormicroenvironment. To improve the expansion/sur-
vival of CAR-modified T lymphocytes, we generated a new vector
encoding 3 molecules: CAR.19 incorporating the co-stimulatory
CD28 endodomain, IL15 and an inducible suicide gene (iCaspase9)
to ensure the safety of modified T cells. We compared the prolifer-
ative capacity, cytotoxic activity and in vivo anti-tumor effects of T
lymphocytes expressing either CAR.19-28z alone or CAR.19-28z,
IL15 and the suicide gene. T lymphocytes were activated with
OKT3/CD28 antibodies and then transduced with retroviral super-
natants. Phenotypic analysis showed 70610% and 7565% transduc-
tion efficiency for iCasp9/CAR19-28z/IL15 andCAR19-28zT cells,
respectively. Only the iCasp9/CAR19-28z /IL15 T cells produced
IL15 (.100pg/mL) after stimulation with CD191 tumor cells. In
co-culture experiments, T cells expressing CAR.19-28z alone or
iCasp9/CAR19-28z/IL15 both completely eliminated CD191 tu-
mor cells within 72 hours. However, labeling with carboxyfluores-
cein diacetate succinimidyl ester (CFSE) showed that the
proliferation of the iCasp9/CAR19-28z/IL151 T cells in response
to CD191 tumor cells was greater than that of CAR.19-28z con-
trol1 T cells. Finally, the activation of the suicide gene iCasp9
with a small-molecule dimerizer (CID 50ng/mL) rapidly induced
.90% apoptosis of T cells expressing iCasp9/CAR19-28z/IL15.
Hence all three transgenes were functional. To assess the antitumor
effects of the modified cells in vivo,we used a xenograft SCIDmouse
model and an in vivo bioluminescence system. CD191 Daudi cells
(1  106) expressing firefly Luciferase (FL) were injected i.p., and
on day 4, mice received i.p iCasp9/CAR19-28z/IL151 or CAR19-
28z1 or control T cells (10  106). By day 30 the tumor signal
was significantly reduced in mice receiving iCasp9/CAR19-28z/
IL151 T cells (ROI \ 7  107) compared to mice receiving
CAR19-28z or control T cells (ROI . 2.0  109). In conclusion,
our data indicate that T cells coexpressing CAR19-28z/IL15/iCasp9
can safely improve anti-leukemia/lymphoma effects.2
DEPLETION OF VASCULAR ENDOTHELIAL PROGENITOR CELLS SIMULTA-
NEOUSLY AMELIORATES GVHD AND INHIBITS TUMOR GROWTH
Penack, O.1, Henke, E.1, Suh, D.1, King, C.1, Smith, M.1, Na, I.-K.1,
Holland, A.1,2, Ghosh, A.1, Lu, S.1, Jenq, R.1, Liu, C.3, May, C.4,
Murphy, G.5, Lu, T.2, Gao, D.2, Mittal, V.2, Benezra, R.1, van den
Brink, M.1 1Memorial Sloan-Kettering Cancer Center; 2Weill Cornell
Medical College; 3University of Florida College of Medicine; 4 ImClone
Systems Incorporated; 5Harvard Medical School
Neo-vascularization (NV) has been implicated in a number of in-
flammatory diseases as well as tumor growth. Both angiogenesis, the
sprouting of resident tissue endothelial cells (ECs), and vasculogen-
esis, the recruitment of bonemarrow (BM)-derived circulating endo-
thelial progenitor cells (EPCs), are thought to participate inNV.We
studied NV and the role of EPCs in murine models of GVHD. Wefound an increased number of donor BM-derivedEPCs in peripheral
blood and BM at different time points during GVHD. We next
quantified NV and found increased numbers of donor-derived ECs
in the liver as well as a higher vessel density in the liver, illeum and
colon. We adoptively transferred selected GFP1 EPCs and ob-
served incorporation into the neo-vasculature of the intestines and
liver during GVHD. Taken together, these data suggest that
GVHD is characterized by increased NV due to vasculogenesis
from donor EPCs. Next we used an antibody (E4G10) against VE-
cadherin, which recognizes a terminal epitope that is exposed on cir-
culating EPCs, but is masked in the established vasculature, and
found a reduction of EPCs in the peripheral blood and BM.We ob-
served that depletion of EPCs was associated with an inhibition of
donor BM-derived NV in the liver, illeum and colon during
GVHD. E4G10 treated recipients had better survival, lower clinical
and histopathological GVHD scores as well as reduced numbers of
tissue-infiltrating CD31 T cells in the liver, illeum and colon. We
transferred sortedGFP1EPCs as well as renal carcinoma (RENCA)
cells to BALB/c recipients and found that EPCs were recruited to the
neo-vasculature of lung metastases. We detected an inhibitory effect
of E4G10 administration on tumor growth, as determined by in vivo
bioluminescence imaging, as well as a survival prolongation in tu-
mor-bearing mice in solid and hematologic tumors. Finally, we per-
formed experiments in which tumor-bearing allo-BMT recipients
received allogeneic T cells. We found that administration of
E4G10 led to a higher rate of tumor-free survival (renal carcinoma,
AML and lymphoma), which was due to both attenuation of GVHD
as well as inhibition of tumor growth.We conclude that depletion of
EPCs is a strategy to simultaneously ameliorate GVHD and inhibit
tumor growth, providing a new approach to improve the overall out-
come of allogeneic hematopoietic stem cell transplantation.3
EPIGENETIC MODULATION OF FOXP3: GENERATION OF CD41CD25- T
CELLS WITH A SUPPRESSOR PHENOTYPE
Choi, J., Schroeder, M., Ritchey, J., DiPersio, J.F.Washington University
School of Medicine, St. Louis, MO
Regulatory T cells (Tregs) contribute to the maintenance of self-
tolerance. Major obstacles for their routine use in human clinical tri-
als to reduce autoimmunity or GvHD include the low number of
Tregs, low yields and efficiencies of purification and severe limita-
tions maintaining suppressor function after ex vivo expansion.
Foxp3 is the master gene responsible for the development and func-
tion of Tregs. Demethylated CpG islands within the Foxp3 locus of
Tregs led us to investigate whether an FDA-approved demethylating
agent, decitabine, could be used to enhance Foxp3 expression and
convert non-Tregs cells into Tregs. Treatment of human
CD41CD25-FOXP3- T cells with decitabine induced FOXP3 ex-
pression. Real time RT-PCR demonstrated levels of mRNA for
FOXP3 that were comparable to that seen in anti-CD3/CD28
bead-activated natural Tregs. This resulted in increased expression
at the protein level in 60% of decitabine-treated cells (dcT). Decita-
bine also induced Foxp3 expression in 80%murine CD41CD25- T
cells. Consistent with these results, decitabine induced marked
increased GFP expression in CD41CD25- T cells from Foxp3-
ires-GFP KI mice. In addition, decitabine injection into sub-lethally
irradiatedmice transplantedwithTCDBM increased the percentage
of CD41Foxp31T cells in the spleens. Of note, dcT could potently
suppress proliferation of CD41CD25- T cells in vitro in response to
both anti-CD3/CD28 bead activation and to allo-APC in mixed
lymphocyte cultures. Transwell experiments demonstrated that the
suppressor function of dcT is cell-contact dependent. Surprisingly,1
